Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.7 - $1.07 $29,119 - $44,512
-41,600 Reduced 27.59%
109,200 $76,000
Q4 2022

Feb 14, 2023

BUY
$0.61 - $5.06 $75,701 - $627,946
124,100 Added 464.79%
150,800 $135,000
Q3 2022

Nov 14, 2022

BUY
$4.19 - $7.95 $111,873 - $212,265
26,700 New
26,700 $160,000

About Satsuma Pharmaceuticals, Inc.


  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.